Nabriva Therapeutics PLC (NBRV)
Stock Price:
$0.570 USD
-0.016 (-2.75%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $0.590 +0.020 (3.49%) Oct 21, 7:20 PM
Key Info
| Market Cap |
82.05M |
| Revenue (ttm) |
8.53M |
| Net Income (ttm) |
-79.54M |
| Shares Out |
143.96M |
| EPS (ttm) |
-0.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$0.570 |
| Previous Close |
$0.586 |
| Change ($) |
-0.016 |
| Change (%) |
-2.75% |
| Day's Open |
0.572 |
| Day's Range |
0.561 - 0.585 |
| Day's Volume |
1,560,363 |
| 52-Week Range |
0.485 - 2.230 |
More Stats
| Market Cap |
82.05M |
| Enterprise Value |
39.47M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
143.96M |
| Float |
n/a |
| EPS (basic) |
-0.09 |
| EPS (diluted) |
-0.88 |
| FCF / Share |
-0.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7.04M |
| Short Ratio |
4.45 |
| Short % of Float |
n/a |
| Beta |
2.23 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
9.62 |
| PB Ratio |
1.91 |
| Revenue |
8.53M |
| Operating Income |
-73.91M |
| Net Income |
-79.54M |
| Free Cash Flow |
-75.61M |
| Net Cash |
42.59M |
| Net Cash / Share |
0.30 |
| Gross Margin |
-199.37% |
| Operating Margin |
-866.57% |
| Profit Margin |
-932.60% |
| FCF Margin |
-886.45% |
| ROA |
-62.13% |
| ROE |
-181.05% |
| ROIC |
-396.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
1 |
| Overweight |
0 |
| Hold |
4 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$1.75*
(207.02% upside)
Low
1.50
Current: $0.570
High
2.00
Target: 1.75
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 9.48 | 9.66 | 5.32 | 6.48 | 3.77 | 2.40 |
| Revenue Growth | -1.81% | 81.54% | -17.94% | 72.07% | 57.09% | - |
| Gross Profit | 9.41 | 9.66 | 5.32 | 6.48 | 3.77 | 2.40 |
| Operating Income | -79.49 | -114 | -73.77 | -55.05 | -27.76 | -10.70 |
| Net Income | -82.76 | -115 | -74.36 | -54.89 | -46.96 | -14.22 |
| Shares Outstanding | 74.20 | 50.80 | 29.83 | 21.48 | 10.58 | 0.32 |
| Earnings Per Share | -0.11 | -0.23 | -0.25 | -0.26 | -0.48 | -4.44 |
| Operating Cash Flow | -71.89 | -72.72 | -69.35 | -48.33 | -21.86 | -11.41 |
| Capital Expenditures | -0.06 | -0.23 | -1.17 | -0.60 | -0.22 | -0.09 |
| Free Cash Flow | -71.95 | -72.95 | -70.52 | -48.93 | -22.07 | -11.49 |
| Cash & Equivalents | 86.59 | 102 | 86.88 | 83.88 | 111 | - |
| Total Debt | 34.50 | 23.72 | 0.23 | - | - | - |
| Net Cash / Debt | 52.08 | 78.51 | 86.65 | 83.88 | 111 | - |
| Assets | 94.11 | 110 | 95.76 | 93.24 | 118 | - |
| Liabilities | 52.84 | 41.79 | 13.70 | 15.98 | 9.01 | - |
| Book Value | 41.27 | 68.63 | 82.07 | 77.26 | 109 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Nabriva Therapeutics PLC |
| Country |
Ireland |
| Employees |
162 |
| CEO |
Theodore R. Schroeder |
Stock Information
| Ticker Symbol |
NBRV |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NBRV |
| IPO Date |
September 18, 2015 |
Description
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.